Literature DB >> 32451346

ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma.

Arnaud Scherpereel1,2, Isabelle Opitz3, Thierry Berghmans4, Ioannis Psallidas5, Markus Glatzer6, David Rigau7, Philippe Astoul8, Servet Bölükbas9, Jeanette Boyd10, Johan Coolen11, Charlotte De Bondt12, Dirk De Ruysscher13, Valerie Durieux14, Corinne Faivre-Finn15, Dean Fennell16, Francoise Galateau-Salle17, Laurent Greillier18, Mir Ali Hoda19, Walter Klepetko19, Aude Lacourt20, Phil McElnay21, Nick A Maskell22, Luciano Mutti23, Jean-Claude Pairon24, Paul Van Schil25, Jan P van Meerbeeck12, David Waller26, Walter Weder3, Giuseppe Cardillo27, Paul Martin Putora6,28.   

Abstract

The European Respiratory Society (ERS)/European Society of Thoracic Surgeons (ESTS)/European Association for Cardio-Thoracic Surgery (EACTS)/European Society for Radiotherapy and Oncology (ESTRO) task force brought together experts to update previous 2009 ERS/ESTS guidelines on management of malignant pleural mesothelioma (MPM), a rare cancer with globally poor outcome, after a systematic review of the 2009-2018 literature. The evidence was appraised using the Grading of Recommendations, Assessment, Development and Evaluation approach. The evidence syntheses were discussed and recommendations formulated by this multidisciplinary group of experts. Diagnosis: pleural biopsies remain the gold standard to confirm the diagnosis, usually obtained by thoracoscopy but occasionally via image-guided percutaneous needle biopsy in cases of pleural symphysis or poor performance status. Pathology: standard staining procedures are insufficient in ∼10% of cases, justifying the use of specific markers, including BAP-1 and CDKN2A (p16) for the separation of atypical mesothelial proliferation from MPM. Staging: in the absence of a uniform, robust and validated staging system, we advise using the most recent 2016 8th TNM (tumour, node, metastasis) classification, with an algorithm for pre-therapeutic assessment. Monitoring: patient's performance status, histological subtype and tumour volume are the main prognostic factors of clinical importance in routine MPM management. Other potential parameters should be recorded at baseline and reported in clinical trials. Treatment: (chemo)therapy has limited efficacy in MPM patients and only selected patients are candidates for radical surgery. New promising targeted therapies, immunotherapies and strategies have been reviewed. Because of limited data on the best combination treatment, we emphasise that patients who are considered candidates for a multimodal approach, including radical surgery, should be treated as part of clinical trials in MPM-dedicated centres. The article has been co-published with permission in the European Respiratory Journal and the European Journal of Cardio-Thoracic Surgery. All rights reserved in respect of European Respiratory Journal, © European Respiratory Society 2020 and European Journal of Cardio-Thoracic Surgery, © European Association for Cardio-Thoracic Surgery 2020. The articles are identical except for minor stylistic and spelling differences in keeping with each journal's style. Either citation can be used when citing this article.

Entities:  

Mesh:

Year:  2020        PMID: 32451346     DOI: 10.1183/13993003.00953-2019

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  32 in total

Review 1.  Challenges in lung and thoracic pathology: molecular advances in the classification of pleural mesotheliomas.

Authors:  Lynnette Fernandez-Cuesta; Lise Mangiante; Nicolas Alcala; Matthieu Foll
Journal:  Virchows Arch       Date:  2021-01-07       Impact factor: 4.064

Review 2.  Mechanisms of resistance to chemotherapy in non-small cell lung cancer.

Authors:  Hye-Young Min; Ho-Young Lee
Journal:  Arch Pharm Res       Date:  2021-02-19       Impact factor: 4.946

3.  Malignant pleural mesothelioma: treatment patterns and humanistic burden of disease in Europe.

Authors:  Adam Moore; Bryan Bennett; Gavin Taylor-Stokes; Laura McDonald; Melinda J Daumont
Journal:  BMC Cancer       Date:  2022-06-23       Impact factor: 4.638

4.  Sneaky Diagnosis of Pleural Malignant Mesothelioma in Thoracic Surgery: All That Glitters Is Not Gold.

Authors:  Riccardo Orlandi; Francesca Bono; Diego Luigi Cortinovis; Giuseppe Cardillo; Ugo Cioffi; Angelo Guttadauro; Emanuele Pirondini; Stefania Canova; Enrico Mario Cassina; Federico Raveglia
Journal:  J Clin Med       Date:  2022-06-06       Impact factor: 4.964

5.  Does the LENT score risk-stratify patients with malignant pleural mesothelioma? An observational study.

Authors:  Bertrand Chollet; Julien Guinde; Sophie Laroumagne; Hervé Dutau; Philippe Astoul
Journal:  Thorac Cancer       Date:  2021-05-05       Impact factor: 3.500

6.  Hyperthermic intrathoracic chemotherapy (HITHOC) should be included in the guidelines for malignant pleural mesothelioma.

Authors:  Marcello Migliore; Michael Ried; Laureano Molins; Marco Lucchi; Marcello Ambrogi; Tamas F Molnar; Hans-Stefan Hofmann
Journal:  Ann Transl Med       Date:  2021-06

Review 7.  Hyperthermic intrathoracic chemotherapy (HITHOC): narrative review of the current literature, recommendations and future studies.

Authors:  Till Markowiak; Christopher Larisch; Hans-Stefan Hofmann; Michael Ried
Journal:  Ann Transl Med       Date:  2021-06

8.  Present and future of hyperthermic intrathoracic chemotherapy (HITHOC) in thoracic surgical oncology.

Authors:  Marcello Migliore
Journal:  Ann Transl Med       Date:  2021-06

9.  Diagnostic Challenges in Epithelioid Pleural Mesothelioma: Case Series with Support from Electron Microscopy.

Authors:  Francesco Fortarezza; Mila Della Barbera; Federica Pezzuto; Francesca Lunardi; Eleonora Faccioli; Giulia Pasello; Federico Rea; Stefania Rizzo; Fiorella Calabrese
Journal:  Diagnostics (Basel)       Date:  2021-05-07

Review 10.  Mouse models for mesothelioma drug discovery and development.

Authors:  Kenneth P Seastedt; Nathanael Pruett; Chuong D Hoang
Journal:  Expert Opin Drug Discov       Date:  2020-12-31       Impact factor: 7.050

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.